The FDA Is Approving Drugs Faster Than It Has Since 2002. The Voucher That Did It Is Already Slipping Its Own Deadlines

On April 1, 2026, the Food and Drug Administration approved Eli Lilly's oral weight-loss pill orforglipron, branded Foundayo, fifty days after the company filed its application and two hundred ninety-four days before the agency's own deadline of January 20, 2027. By the FDA's account it was the fastest approval of a new molecular entity since 2002. For a drug expected to reach millions of patients, the review took less time than a studious undergraduate spends on a term paper.

That single decision is the clearest window into a quieter change in how American medicines now reach the market. Through the first nine months of 2026 the FDA approved forty-four novel drugs, against thirty-two in the same stretch of 2025. The agency is moving faster than it has in a generation, and it has a specific instrument to thank for it. The instrument also explains why the speed is less of an unalloyed win than the headline numbers suggest.

The voucher rewrote the clock, not the science

The engine here is the Commissioner's National Priority Voucher, launched in 2025 under then-commissioner Marty Makary. A voucher does not lower the evidentiary bar a drug must clear. It rewrites the schedule around it. Instead of routing an application sequentially through the agency's many offices over the standard ten-to-twelve-month cycle, the FDA convenes a single team that reviews in parallel, accepts portions of the submission on a rolling basis, and, in Makary's framing, strips out the idle time between steps. The stated target is a decision in one to two months.

Orforglipron is the proof of concept. Its approval rested on two randomized, double-blind trials, the same kind of evidence a standard review would demand. What compressed was the calendar, not the dossier. That distinction matters, because it is the foundation of the FDA's defense of the program: faster, the agency insists, does not mean looser.

Forty-four approvals is a real number, not a press release

It would be easy to dismiss a self-congratulatory agency metric, but the throughput is visible in the count. Forty-four novel approvals through September, up from thirty-two, is not a rounding artifact; it is roughly a third more new medicines reaching patients in the same window a year earlier. For someone waiting on a therapy for a rare disease, that acceleration is the entire point, and it is worth stating plainly before complicating it.

The first voucher cohort was built to make exactly that case. It leaned toward genuine unmet need: Revolution Medicines' candidate for pancreatic cancer, Disc Medicine's bitopertin for a form of porphyria, Achieve Life Sciences' cytisinicline for nicotine-vaping addiction, Dompé's cenegermin for a rare cause of blindness. These are the drugs a priority program is supposed to exist for.

The flagship cohort is already missing its own deadlines

Here the story turns. A program that promises one-to-two-month decisions is only as credible as its slowest case, and several of the earliest awardees have slipped. Orforglipron itself saw its target date pushed into April from an earlier late-March expectation. Awardees backed by Sanofi, Boehringer Ingelheim, and Disc Medicine have all had their timelines extended despite holding the golden ticket. The FDA built an escape hatch into the design, reserving the right to extend any review as needed, which is prudent regulation but also an admission that the one-to-two-month headline is a ceiling, not a floor.

The uneven delivery undercuts the cleanest version of the program's pitch. If the vouchers reliably collapsed review times, every awardee would clear quickly. That some do and some do not suggests the speed depends less on the voucher than on the specific drug and the specific questions it raises, which is roughly what the old system already accounted for through priority review.

The vouchers increasingly buy things that are not speed

The more telling drift is in what the FDA asks for in return. Vouchers are granted, in the agency's own description, to companies that agree to increase affordability, bring manufacturing onshore as a matter of national security, or address an unmet public-health need. A second batch awarded in late 2025 brought the total to fifteen, and notably, most of that cohort went to drugs already on the market rather than to novel therapies waiting in line. One award was tied to the domestic manufacturing of a common antibiotic.

Read that carefully, because it reframes the whole enterprise. A tool introduced as a way to speed breakthrough medicines to patients is increasingly being used to extract pricing and supply-chain commitments from large pharmaceutical companies. That may be defensible industrial policy. But it is industrial policy conducted through the drug-approval queue, and it means a voucher's value is now partly a negotiating chip rather than a pure patient-benefit judgment. The selection process has drawn enough criticism on transparency grounds that the FDA held a public hearing in June 2026 to defend how it picks winners.

Compressed review and a leadership vacuum raise the stakes

Speed has a cost that does not show up until later. Much of the safety understanding of a new drug is assembled in the back-and-forth of a review, in the questions an agency raises after filing and the answers a sponsor must produce. Compress that window and there is simply less of that exchange. Orforglipron carries a boxed warning for thyroid C-cell tumors, the FDA's most serious label caution, which is a reminder that these are not low-consequence products moving through an expedited lane.

The institutional backdrop sharpens the concern. Makary, the program's architect, resigned in May 2026 after roughly thirteen months in office. His nominated successor, Heidi Overton, sat for a Senate confirmation hearing on September 24, 2026. A fast-track system that concentrates review authority in a hand-picked council is more exposed than a diffuse one to who, exactly, is running it, and the agency is changing hands with the program still in its pilot phase.

What this actually means

The reflexive takes are both wrong. This is not simply regulatory capture dressed up as efficiency, and it is not a clean victory for patients over bureaucracy. The forty-four approvals are real, the fifty-day orforglipron decision is real, and for patients with no good options that acceleration is a genuine gain.

What has changed is subtler and more durable: the FDA has given itself a lever that bundles approval speed with pricing, manufacturing, and national-priority commitments, operated by a small council, during a leadership transition, with uneven results so far. The right thing to watch is not the next record-fast approval. It is whether the program's safety record holds up over the next two years, whether the vouchers keep migrating toward already-marketed drugs and policy concessions, and what Overton, if confirmed, does with a tool built around the discretion of the commissioner who leaves. The speed was never the question. What the agency is willing to trade for it is.

Sources

• FDA, "FDA Approves First New Molecular Entity Under National Priority Voucher Program" — https://fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
• Lachman Consultants, first NME approved through CNPV — https://www.lachmanconsultants.com/2026/04/first-nme-approved-through-commissioners-national-priority-voucher-cnpv-program/
• RTTNews, "Biotech Stocks Facing FDA Decision In October 2026" (44 vs 32 novel approvals; Makary resignation; Overton hearing) — https://www.rttnews.com/3694685/biotech-stocks-facing-fda-decision-in-october-2026.aspx
• BioSpace, "Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed" — https://www.biospace.com/fda/pressure-on-purpose-questioned-as-second-round-of-fda-priority-review-vouchers-revealed
• GLP1 Clinics, "FDA Delays Orforglipron Decision" (awardee delays: Sanofi, Boehringer Ingelheim, Disc Medicine) — https://glp1clinics.org/blog/fda-delays-orforglipron-decision-april-2026-2026-04-01
• Stockopedia / Reuters, "US FDA announces recipients of national priority vouchers" (first-cohort awardees) — https://www.stockopedia.com/share-prices/merck-k-ga-a-ETR:MRK/news/us-fda-announces-recipients-of-national-priority-vouchers-updated-019e69ed-4f6e-7192-9424-b73dd1dedc8e/